Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
CC transcript
Inv. presentation

Capstone Therapeutics Corp. (CAPS) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/25/2019 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
09/09/2019 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
08/26/2019 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Amendment to the Restated Certificate of Incorporation of Capstone Therapeutics Corp",
"Contingent Value Rights Agreement",
"Third Amendment to the Securities Purchase, Loan and Securities Agreement"
08/20/2019 SC 13D/A BP Peptides, LLC reports a 39% stake in Capstone Therapeutics Corp.
08/13/2019 10-Q Quarterly Report for the period ended June 30, 2019
07/10/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/03/2019 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
07/03/2019 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
05/31/2019 SC 13E3 Form SC 13E3 - Going private transaction by certain issuers:
05/31/2019 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/13/2019 10-Q Quarterly Report for the period ended March 31, 2019
03/22/2019 10-K Annual Report for the period ended December 31, 2018
03/21/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2019 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/19/2019 SC 13D/A BP Peptides, LLC reports a 38% stake in Capstone Therapeutics Corp.
03/19/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Securities Purchase, Loan and Security Agreement dated March 15, 2019, by and between Capstone Therapeutics, Corp. and BP Peptides, LLC"
02/13/2019 SC 13G/A SUBIN NEIL S reports a 13.9% stake in Capstone Therapeutics Corp.
02/11/2019 SC 13G Alimco Financial Corp reports a 0.2% stake in Capstone Therapeutics Corp.
02/04/2019 3 Form 3 - Initial statement of beneficial ownership of securities:
12/28/2018 4 SUBIN NEIL S (10% Owner) has filed a Form 4 on Capstone Therapeutics Corp.
Txns: Sold 206,000 shares @ $0.052, valued at $10.7k
Bought 103,000 shares @ $0.052, valued at $5.4k
11/20/2018 SC 13D/A BP Peptides, LLC reports a 37.5% stake in Capstone Therapeutics Corp.
11/06/2018 10-Q Quarterly Report for the period ended September 30, 2018
08/13/2018 10-Q Quarterly Report for the period ended June 30, 2018
05/18/2018 SC 13D/A BP Peptides, LLC reports a 36.4% stake in Capstone Therapeutics Corp.
05/11/2018 10-Q Quarterly Report for the period ended March 31, 2018
05/07/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "License Agreement dated May 2, 2018, by and between LipimetiX Development, Inc. and ANJI Pharmaceuticals Inc",
"LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China NATICK, Mass., May 07, 2018 -- LipimetiX Development, Inc. announced today that Anji Pharmaceuticals, Inc. has entered a licensing agreement for the LipimetiX platform of peptides for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China. The Anji Pharma’s license provides exclusive rights to and use of the LipimetiX patent portfolio of Apo E mimetic peptides and formulations in the above-mentioned territory. Terms include an upfront licensing payment to LipimetiX of US$2.0 million, multiple additional cash payments up..."
02/28/2018 10-K Annual Report for the period ended December 31, 2017
02/01/2018 4 Lipman Matthew E. (10% Owner) has filed a Form 4 on Capstone Therapeutics Corp.
Txns: Acquired 1 options to buy @ $0.075, valued at $0.1
02/01/2018 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/01/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "First Amendment to Securities Purchase Loan and Security Agreement dated January 30, 2018, by and between Capstone Therapeutics, Corp. and BP Peptides, LLC",
"Warrant to Purchase Common Stock"
01/23/2018 SC 13G SUBIN NEIL S reports a 14.1% stake in Capstone Therapeutics Corp.
01/22/2018 3 SUBIN NEIL S (10% Owner) has filed a Form 3 on Capstone Therapeutics Corp.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy